Ionis Pharmaceuticals (NASDAQ:IONS) EVP Holly Kordasiewicz Sells 362 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Holly Kordasiewicz sold 362 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $84.30, for a total transaction of $30,516.60. Following the completion of the sale, the executive vice president directly owned 22,096 shares in the company, valued at $1,862,692.80. This trade represents a 1.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $64.27 on Friday. The stock has a fifty day simple moving average of $76.12 and a two-hundred day simple moving average of $77.41. Ionis Pharmaceuticals, Inc. has a 1-year low of $40.03 and a 1-year high of $86.74. The firm has a market cap of $10.62 billion, a price-to-earnings ratio of -31.05 and a beta of 0.36. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The firm had revenue of $246.09 million for the quarter, compared to analyst estimates of $195.56 million. During the same period in the previous year, the company posted ($0.93) earnings per share. The business’s revenue was up 86.4% on a year-over-year basis. Analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on IONS shares. The Goldman Sachs Group upped their price objective on shares of Ionis Pharmaceuticals from $74.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Leerink Partners boosted their price target on shares of Ionis Pharmaceuticals from $122.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Jefferies Financial Group dropped their price target on shares of Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $111.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.80.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Brown Brothers Harriman & Co. purchased a new position in Ionis Pharmaceuticals during the 4th quarter valued at about $27,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Ionis Pharmaceuticals in the first quarter worth about $30,000. Quarry LP purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter worth about $38,000. Johnson Financial Group Inc. bought a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $44,000. Finally, Laurel Wealth Advisors LLC bought a new position in Ionis Pharmaceuticals in the 4th quarter valued at $47,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals News Summary

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Negative Sentiment: Ionis and AstraZeneca said the Phase 3 CARDIO-TTRansform trial for eplontersen in ATTR-CM did not meet its primary endpoint, a key clinical and commercial setback for the program. Article Title
• Negative Sentiment: Reuters reported that AstraZeneca-Ionis’ Wainua failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in the late-stage study, reinforcing concerns about the franchise. Article Title
• Negative Sentiment: Shares saw unusually large put-buying, suggesting some traders are positioning for further downside after the trial disappointment.
• Negative Sentiment: Two insiders disclosed stock sales under pre-arranged 10b5-1 plans, including Director Allene M. Diaz and EVP Holly B. Kordasiewicz, which may add to near-term investor caution.
• Neutral Sentiment: Needham lowered its price target to $86 from $105 but reiterated a Buy rating, indicating continued optimism despite the reduced valuation outlook. Article Title
• Neutral Sentiment: Some coverage notes that investors are debating whether the selloff creates a buying opportunity, but this is sentiment-driven rather than a fundamental catalyst. Article Title

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.